PURPOSE: Caspase-14 is unique among caspase family proteases in that its proteolytic processing has been principally associated with epithelial cell differentiation rather than apoptosis or inflammation. We investigated caspase-14 expression in several types of human epithelial malignancy by immunohistochemistry, correlating results with stage, histologic grade, and patient survival. EXPERIMENTAL DESIGN: Tumor-associated alterations in caspase-14 expression were observed for cervical, ovarian, breast, gastric, and colon cancers. RESULTS: In cervical (n = 445), ovarian (n = 91), and colon (n = 106) specimens, expression of caspase-14 was significantly reduced in cancers compared with normal epithelium. Decreases in caspase-14 immunopositivity correlated with the histologic progression of cervical cancer (P < 0.0001, ANOVA). In localized gastric cancers, caspase-14 immunostaining was significantly lower in poorly differentiated tumors compared with well-differentiated tumors (P = 0.02, Pearson's chi(2) analysis). Lower caspase-14 expression was associated with advanced clinical stage in ovarian cancer (P = 0.04, ANOVA) and with shorter overall survival among ovarian cancer patients with serous tumors (n = 62) in both univariate (P = 0.005) and multivariate (P = 0.03) analysis. Lower caspase-14 expression correlated with shorter overall survival among patients with T(3)N(0)M(0) stage gastric cancers (n = 94; P = 0.006, log-rank test). In contrast to cervical, ovarian, and colon cancers, caspase-14 expression was increased in ductal carcinoma in situ and invasive cancers compared with normal mammary epithelium (P = 0.001, t test). CONCLUSIONS: The findings reveal tumor-specific alterations in caspase-14 expression and suggest that differences in its expression may define subsets of epithelial cancers with distinct clinical behaviors.
PURPOSE:Caspase-14 is unique among caspase family proteases in that its proteolytic processing has been principally associated with epithelial cell differentiation rather than apoptosis or inflammation. We investigated caspase-14 expression in several types of human epithelial malignancy by immunohistochemistry, correlating results with stage, histologic grade, and patient survival. EXPERIMENTAL DESIGN:Tumor-associated alterations in caspase-14 expression were observed for cervical, ovarian, breast, gastric, and colon cancers. RESULTS: In cervical (n = 445), ovarian (n = 91), and colon (n = 106) specimens, expression of caspase-14 was significantly reduced in cancers compared with normal epithelium. Decreases in caspase-14 immunopositivity correlated with the histologic progression of cervical cancer (P < 0.0001, ANOVA). In localized gastric cancers, caspase-14 immunostaining was significantly lower in poorly differentiated tumors compared with well-differentiated tumors (P = 0.02, Pearson's chi(2) analysis). Lower caspase-14 expression was associated with advanced clinical stage in ovarian cancer (P = 0.04, ANOVA) and with shorter overall survival among ovarian cancerpatients with serous tumors (n = 62) in both univariate (P = 0.005) and multivariate (P = 0.03) analysis. Lower caspase-14 expression correlated with shorter overall survival among patients with T(3)N(0)M(0) stage gastric cancers (n = 94; P = 0.006, log-rank test). In contrast to cervical, ovarian, and colon cancers, caspase-14 expression was increased in ductal carcinoma in situ and invasive cancers compared with normal mammary epithelium (P = 0.001, t test). CONCLUSIONS: The findings reveal tumor-specific alterations in caspase-14 expression and suggest that differences in its expression may define subsets of epithelial cancers with distinct clinical behaviors.
Authors: Marie-Liesse Asselin-Labat; Kate D Sutherland; François Vaillant; David E Gyorki; Di Wu; Sheridan Holroyd; Kelsey Breslin; Teresa Ward; Wei Shi; Mary L Bath; Siddhartha Deb; Stephen B Fox; Gordon K Smyth; Geoffrey J Lindeman; Jane E Visvader Journal: Mol Cell Biol Date: 2011-09-19 Impact factor: 4.272
Authors: Frederic Luciano; Maryla Krajewska; Paulina Ortiz-Rubio; Stan Krajewski; Dayong Zhai; Benjamin Faustin; Jean-Marie Bruey; Beatrice Bailly-Maitre; Alan Lichtenstein; Siva Kumar Kolluri; Arnold C Satterthwait; Xiao-Kun Zhang; John C Reed Journal: Blood Date: 2007-01-16 Impact factor: 22.113
Authors: Mengjie Wu; Isamu Kodani; Douglas Dickinson; Frank Huff; Kalu U E Ogbureke; Haiyan Qin; Senthil Arun; Rachel Dulebohn; Mohamed Al-Shabrawey; Amany Tawfik; Susan Prater; Jill Lewis; John Wataha; Regina Messer; Stephen Hsu Journal: Anticancer Res Date: 2009-10 Impact factor: 2.480
Authors: Maria L C Powell; Jennifer A Smith; Mathew E Sowa; J Wade Harper; Thomas Iftner; Frank Stubenrauch; Peter M Howley Journal: J Virol Date: 2010-02-24 Impact factor: 5.103
Authors: Maryla Krajewska; Shinichi Kitada; Jane N Winter; Daina Variakojis; Alan Lichtenstein; Dayong Zhai; Michael Cuddy; Xianshu Huang; Frederic Luciano; Cheryl H Baker; Hoguen Kim; Eunah Shin; Susan Kennedy; Allen H Olson; Andrzej Badzio; Jacek Jassem; Ivo Meinhold-Heerlein; Michael J Duffy; Aaron D Schimmer; Ming Tsao; Ewan Brown; Anne Sawyers; Michael Andreeff; Dan Mercola; Stan Krajewski; John C Reed Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Svetlana Baranovskaya; Yolanda Martin; Sergio Alonso; Ksenia L Pisarchuk; Mario Falchetti; Yuichi Dai; Sophia Khaldoyanidi; Stan Krajewski; Inna Novikova; Yuri S Sidorenko; Manuel Perucho; Sergei R Malkhosyan Journal: Clin Cancer Res Date: 2009-07-07 Impact factor: 12.531